Sophoridine tricyclic derivative and application of sophoridine tricyclic derivative in preparation of anti-hepatic fibrosis or anti-primary liver cancer drugs

The invention discloses a sophoridine tricyclic derivative or a pharmaceutical salt thereof. The structural general formula of the sophoridine tricyclic derivative is shown in the specification, wherein # imgabs0 # R1 is selected from hydrogen, C1-C20 straight-chain alkyl and C1-C20 branched-chain-containing alkyl; in-vitro experiments prove that the sophoridine tricyclic derivative can inhibit activation of hepatic stellate cells induced by TGF-beta, improve mouse liver injury and liver fibrosis induced by CCl4 and bile duct ligation, inhibit activation of a TGF-beta/Smads signal channel and inhibit primary liver cancer of mice induced by diethyl nitrosamine at the same time. Therefore, the invention provides a new basis for the sophoridine tricyclic derivative to treat, relieve or improve hepatic fibrosis or primary liver cancer. 本发明公开了一种槐定碱三环衍生物或其药用盐，结构通式如下所示：#imgabs0#R1选自氢、C1～C20直链烷基、C1～C20含有支链的烷基；#imgabs1#本发明通过体外实验验证，槐定碱三环衍生物可抑制TGF-β诱导的肝星状细胞的活化，改善CCl4、胆管结扎诱导的小鼠肝损伤及肝纤维化，抑制TGF-β/Smads信号通路活化，同时还能抑制二乙基亚硝胺诱导的